Effect of thymalin on adaptive immunity in complex therapy for patients with COVID-19

Results of comparative assessment of level of antibodies of IgG to SARS-CoV-2 in dynamics at standard and complex methods of treatment with use of medicinal peptide medicine of a timus of a timalin for patients with COVID-19 are presented in article. It was found that as a result of standard treatment, patients showed a decrease in antibody levels by 53% after 104 days. The addition of thymalin to standard therapy slowed down the decline of this indicator. So, a similar indicator in patients who took thymalin was only 21%. This contributed to maintaining strained adaptive immunity. The detected immunomodulatory properties of the preparation of thymalin with respect to COVID-19 can be reflected both in the formation of an effective immune layer of the population through natural immunization, and in the process of antibody formation during vaccination of target contingents.

1. Rokni M., Ghasemi V., Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS. Rev. Med. Virol. 2020;30(3):e2107. DOI: 10.1002/rmv.2107

2. Leung D.T., Tam F.C., Ma C.H., Chan P.K., Cheung J.L.K., Niu H. et al. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J Infect. Dis. 2004;190(2):379–86. DOI: 10.1086/422040

3. Tan Y., Liu F., Xu X., Ling Y., Huang W., Zhu Z. et al. Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. Front. Med. 2020;14:746–751. DOI: 10.1007/s11684-020-0822-5

4. Wu F., Wang A., Liu M., Wang Q., Chen J., Xia S. et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered 2 patient cohort and their implications. medRxiv. 2020. DOI: 10.1101/2020.03.30.20047365

5. Yiğenoğlu T.N., Hacıbekiroğlu T., Berber İ., Dal M.S., Baştürk A., Namdaroğlu S. et al. Convalescent plasma therapy in patients with COVID-19. J. Clin. Apher. 2020;35(4):367–373. DOI: 10.1002/jca.21806

6. Krammer F., Simon V. Serology assays to manage COVID-19. Science. 2020;368(6495):1060–1061. DOI: 10.1126/science.abc1227

7. Wajnberg A., Amanat F., Firpo A., Altman D.R., Bailey M.J., Mansour M. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227–1230. DOI: 10.1126/science.abd7728

8. Long Q. X., Tang X-J., Shi Q-L., Li Q., Deng H-J., Yuan J. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020;26(8):1200–1204. DOI:10.1038/s41591-020-0965-6

9. Ripperger T.J., Uhrlaub J.L., Watanabe M., Wong R., Castaneda Y., Pizzato H.A. et al. Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure. medRxiv. 2020. DOI: 10.1101/2020.08.14.20174490

10. Tillett R.L., SevinskyJ.R., Hartley P.D., Kerwin H., Crawford N., Gorzalski A. et al. Genomic evidence for reinfection with SARSCoV-2: a case study. Lancet Infect. Dis. 2020;21(1):52–8. DOI: 10.1016/S1473-3099(20)30764-7

11. Хавинсон В.Х. Лекарственные пептидные препараты: прошлое, настоящее, будущее. Клиническая медицина. 2020;98(3):165– 177. [Khavinson V.Kh. Peptide medicines: past, present, future. Klinicheskayа Meditsina. 2020;98(3):165–177. (in Russian)]. DOI: http://dx.DOI.org/10.30629/0023-2149-2020-98-3-165-177

12. Хавинсон В.Х., Кузник Б.И. Осложнения у больных CОVID-19. Предполагаемые механизмы коррекции. Клиническая медицина. 2020;98(4):256–5. [Khavinson V.Kh., Кuznik B.I. Complications in CОVID-19 patients. Suggested mechanisms of correction. Klinicheskayа Meditsina. 2020;98(4):256–65. (in Russian)]. DOI: http://dx.DOI.org/10.30629/0023-2149-2020-98-4-256-265

13. Хавинсон В.Х., Кузник Б.И., Рыжак Г.А. Пептидные геропротекторы — эпигенетические регуляторы физиологических функций организма. СПб.: РГПУ им. А.И. Герцена. 2014:271. [Khavinson V.Kh., Kuznik B.I., Ryzhak G.A. Peptide geroprotectors — epigenetic regulators of the physiological functions of the organism. SPb.: RGPU im. A.I. Gertsena. 2014:271. (in Russian)]

14. Белокрылов Г.А., Морозов В.Г., Хавинсон В.Х., Софронов Б.Н. Влияние низкомолекулярных экстрактов из гетерологичных тимуса, эпифиза и гипоталамуса на иммунный ответ у мышей. Бюллетень экспериментальной биологии и медицины.1976;2:202–4. [Belokrylov G.A., Morozov V.G., Khavinson V.Kh., Sofronov B.N. Influence of low molecular weight extracts from heterologous thymus, pineal gland and hypothalamus on the immune response in mice. Byulleten’ eksperimental’noy biologii i meditsiny. 1976;2:202– 4. (in Russian)]

15. Белокрылов Г.А., Морозов В.Г., Хавинсон В.Х., Софронов Б.Н. Низкомолекулярная гомогенная фракция тимуса, стимулирующая иммуногенез. Бюллетень экспериментальной биологии и медицины.1977;7:56–8. [Belokrylov G.A., Morozov V.G., Khavinson V.Kh., Sofronov B.N. Low molecular weight homogeneous fraction of the thymus that stimulates immunogenesis. Byulleten’ eksperimental’noy biologii i meditsiny.1977;7:56–8. (in Russian)]

16. Theel E.S., Harring J., Hilgart H., Granger D. Performance characte ristics of four high-throughput immunoassays for detection of IgG аntibodies against SARS-CoV-2. J. Clin. Microbiol. 2020;58(8):e01243–20. DOI: 10.1128/JCM.01243-20